Europe will have to wait for Ascendis Pharma's weekly growth hormone

The Danish biotech firm will not be launching its weekly drug until mid-2023 in Europe, despite already having marketing authorization in the region, Ascendis reveals in its second-quarter report.

Photo: Kevin Grønnemann

Ascendis Pharma, which is based in Copenhagen, Denmark, is busy getting growth hormone Skytrofa established on the US market, which means Europe will have to take a back seat.

After a positive November recommendation from an expert committee, the EMA approved the drug in January this year, meaning the once-weekly drug is ready for the European market under the name of its active ingredient, Lonapegsomatropin.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs